Phase II study of mitozolomide (M & B 39,565) in head and neck cancer
Authors:
- 1 December 1989
- journal article
- conference paper
- Published by Springer Nature in Medical Oncology and Tumor Pharmacotherapy
- Vol. 6 (4) , 267-269
Abstract
Nineteen patients with advanced head and neck cancer were given mitozolomide (MTZ), i.v. infusion, every 6 weeks. The starting dose was 100 mg m−2. When it was well tolerated, dose escalation was performed up to 110–115 mg m−2. The limiting toxicity was thrombocytopenia, often mild, but occasionally severe, with hemorrhage and the need for platelet transfusions in two patients. The platelet nadir was 85 × 109 1−1 (11–225). No response was observed in 14 evaluable patients. MTZ, according to this schedule and dosage does not show significant activity in human squamous cell head and neck cancer.Keywords
This publication has 4 references indexed in Scilit:
- ACTIVITY OF MITOZOLOMIDE (NSC 353451), A NEW IMIDAZOTETRAZINE, AGAINST XENOGRAFTS FROM HUMAN MELANOMAS, SARCOMAS, AND LUNG AND COLON CARCINOMAS1985
- PHASE-I CLINICAL-TRIAL OF MITOZOLOMIDE1985
- Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agentJournal of Medicinal Chemistry, 1984
- DNA CROSS-LINKING AND CYTO-TOXICITY IN NORMAL AND TRANSFORMED HUMAN-CELLS TREATED INVITRO WITH 8-CARBAMOYL-3-(2-CHLOROETHYL)IMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE1984